Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Show all queries
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00430729
Registration number
NCT00430729
Ethics application status
Date submitted
1/02/2007
Date registered
2/02/2007
Date last updated
30/11/2016
Titles & IDs
Public title
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
Query!
Scientific title
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52 Weeks Double Blind Study With 500mcg Roflumilast Once Daily Versus Placebo. Ratio-Study.
Query!
Secondary ID [1]
0
0
BY217/M2-112
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease
0
0
Query!
COPD
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Roflumilast
Treatment: Drugs: Roflumilast
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The frequency of patients experiencing at least one moderate or severe exacerbation during the treatment period.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Primary outcome [2]
0
0
Change in FEV1 from baseline during the treatment period.
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [1]
0
0
Pulmonary function variables; quality of life variables;patient diary variables;safety
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
Main
- FEV1/FVC ratio (post-bronchodilator) =70%
- FEV1 (post-bronchodilator) =50% of predicted
- Current smoker or ex-smoker
- Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of
within 4 weeks prior to baseline
- Availability of a chest x-ray dated a maximum of 6 months prior to study baseline
visit B0 or a willingness to have a chest x-ray performed before baseline
Main
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4
weeks prior to baseline
- Lower respiratory tract infection not resolved 4 weeks prior to baseline
- Diagnosis of asthma and/or other relevant lung disease
- Known alpha-1-antitrypsin deficiency
- Need for long-term oxygen therapy defined as =16 hours/day
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
ALTANA Pharma - Cities in Australia
Query!
Recruitment postcode(s) [1]
0
0
- Cities in Australia
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Cities in Austria
Query!
Country [2]
0
0
Canada
Query!
State/province [2]
0
0
Cities in Canada
Query!
Country [3]
0
0
France
Query!
State/province [3]
0
0
Cities in France
Query!
Country [4]
0
0
Hungary
Query!
State/province [4]
0
0
Cities in Hungary
Query!
Country [5]
0
0
Italy
Query!
State/province [5]
0
0
Cities in Italy
Query!
Country [6]
0
0
Netherlands
Query!
State/province [6]
0
0
Cities in the Netherlands
Query!
Country [7]
0
0
Poland
Query!
State/province [7]
0
0
Cities in Poland
Query!
Country [8]
0
0
Portugal
Query!
State/province [8]
0
0
Cities in Portugal
Query!
Country [9]
0
0
Russian Federation
Query!
State/province [9]
0
0
Cities in the Russian Federation
Query!
Country [10]
0
0
South Africa
Query!
State/province [10]
0
0
Cities in South Africa
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Cities in Spain
Query!
Country [12]
0
0
Switzerland
Query!
State/province [12]
0
0
Cities in Switzerland
Query!
Country [13]
0
0
United Kingdom
Query!
State/province [13]
0
0
Cities in the United Kingdom
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on
exacerbation rate and pulmonary function as well as quality of life in patients with chronic
obstructive pulmonary disease (COPD).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00430729
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
AstraZeneca AstraZeneca
Query!
Address
0
0
AstraZeneca
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00430729
Download to PDF
Show all queries